

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 68

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–105) and Recommended (1–66) International Nonproprietary Names can be found in *Cumulative List No. 14, 2011* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 68

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–105) et recommandées (1–66) dans la *Liste récapitulative No. 14, 2011* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 68

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–105) y Recomendadas (1–66) se encuentran reunidas en *Cumulative List No. 14, 2011* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:
Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

acidum deoxycholicum

deoxycholic acid

3 α ,12 α -dihydroxy-5 β -cholan-24-oic acid


acide désoxycholique

acide 3 α ,12 α -dihydroxy-5 β -cholan-24-oïque

ácido desoxicólico

ácido 3 α ,12 α -dihidroxi-5 β -colan-24-oico

C₂₄H₄₀O₄



acidum florilglutamicum (¹⁸F)

florilglutamic acid (¹⁸F)

(4S)-4-(3-[¹⁸F]fluoropropyl)-L-glutamic acid


acide florilglutamique (¹⁸F)

acide (4S)-4-(3-[¹⁸F]fluoropropyl)-L-glutamique

ácido florilglutámico (¹⁸F)

ácido (4S)-4-(3-[¹⁸F]fluoropropil)-L-glutámico

C₈H₁₄¹⁸FNO₄



acidum tiazoticum

tiazotic acid

[(5-methyl-1H-1,2,4-triazol-3-yl)sulfanyl]acetic acid


acide tiazotique

acide [(5-méthyl-1H-1,2,4-triazol-3-yl)sulfanyl]acétique

ácido tiazótico

ácido [(5-metil-1H-1,2,4-triazol-3-il)sulfanil]acético

C₅H₇N₃O₂S



amitifadinum


amitifadine

(1*R*,5*S*)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane

amitifadine

(1*R*,5*S*)-1-(3,4-dichlorophényl)-3-azabicyclo[3.1.0]hexane

amitifadina

(1*R*,5*S*)-1-(3,4-diclorofenil)-3-azabicio[3.1.0]hexanoC₁₁H₁₁Cl₂N**bamosiranum**

bamosiran

siRNA inhibitor of β_2 -adrenergic receptor production;
 RNA duplex of cytidylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-thymidylyl-(3'→5')-thymidine with thymidylyl-(5'→3')-thymidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adenylyl-(5'→3')-adenylyl-(5'→3')-cytidylyl-(5'→3')-adenylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adenylyl-(5'→3')-cytidylyl-(5'→3')-adenylyl-(5'→3')-cytidylyl-(5'→3')-uridylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-cytidine

bamosiran

petit ARN interférant (siRNA) inhibiteur de la production du récepteur adrénergique β_2 ;

duplex ARN du brin cytidylyl-(3'→5')-adénylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-adénylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-thymidylyl-(3'→5')-thymidine avec le brin anti-sens thymidylyl-(5'→3')-thymidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adénylyl-(5'→3')-adénylyl-(5'→3')-cytidylyl-(5'→3')-adénylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adénylyl-(5'→3')-cytidylyl-(5'→3')-uridylyl-(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-cytidine

bamosirán

ARN interferente pequeño (siRNA) inhibidor de la producción del receptor adrenérgico β_2

ARN dúplex de la cadena citidilil-(3'→5')-adenilil-(3'→5')-uridilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-uridilil-(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-timidilil-(3'→5')-timidina con la cadena antisentido timidilil-(5'→3')-timidilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-adenilil-(5'→3')-adenilil-(5'→3')-citidilil-(5'→3')-adenilil-(5'→3')-citidilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-adenilil-(5'→3')-citidilil-(5'→3')-adenilil-(5'→3')-citidilil-(5'→3')-uridilil-(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-citidina

C₄₀₁H₅₀₀N₁₅₀O₂₉₀P₄₀

(3'-5')CAUUGUGCAUGUGAUCCAG-dT-dT
 (5'-3')dT-dT-GUAACACGUACACUAGGUC

brexpiprazolum


brexpiprazole

7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1*H*)-one

brexpiprazole

7-{4-[4-(1-benzothiophén-4-yl)pipérazin-1-yl]butoxy}quinoléin-2(1*H*)-one

brexpiprazol

7-{4-[4-(1-benzotiofen-4-il)piperazin-1-il]butoxi}quinolin-2(1*H*)-ona $C_{25}H_{27}N_3O_2S$ **buparlisibum**

buparlisib


5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine

buparlisib

5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluorométhyl)pyridin-2-amine

buparlisib

5-[2,6-bis(morfolin-4-il)pirimidin-4-il]-4-(trifluorometil)piridin-2-amina

 $C_{18}H_{21}F_3N_6O_2$ **camicinalum**


camicinal

1-{4-[(3-fluorophenyl)amino]piperidin-1-yl}-2-{4-[[[(3*S*)-3-methylpiperazin-1-yl]methyl]phenyl]ethan-1-one

camicinal

1-{4-[(3-fluorophényl)amino]pipéridin-1-yl}-2-{4-[[[(3*S*)-3-méthylpipérazin-1-yl]méthyl]phényl]éthan-1-one

camicinal

1-{4-[(3-fluorofenil)amino]piperidin-1-il}-2-{4-[[[(3*S*)-3-metilpiperazin-1-il]metil]fenil]etan-1-ona $C_{25}H_{33}FN_4O$ 

caplacizumabum #

caplacizumab

immunoglobulin VH-linker-VH fragment, anti-[*Homo sapiens* VWF (von Willebrand factor) A1 domain], humanized monoclonal antibody;
 VH-linker-VH chain (1-259) [humanized VH (*Homo sapiens*IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-128))] -
 trialanyl linker (129-131) -[humanized VH (*Homo sapiens*IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21] (132-259)]

caplacizumab

immunoglobuline fragment VH-linker-VH, anti-[*Homo sapiens* VWF (facteur de von Willebrand) domaine A1], anticorps monoclonal humanisé;
 chaîne VH-linker-VH (1-259) [VH humanisé (*Homo sapiens*IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-128))] -
 trialanyl linker (129-131) -[VH humanisé (*Homo sapiens*IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21] (132-259)]

caplacizumab

immunoglobulina fragmento VH-conector-VH, anti-[VWF (factor de von Willebrand) de *Homo sapiens* dominio A1], anticuerpo monoclonal humanizado;
 cadena VH-conector-VH (1-259) [VH humanizado (*Homo sapiens*IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-128))] -trialanil conector (129-131) -[VH humanizado (*Homo sapiens*IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21] (132-259)]

```
EVQLVESGGG LVQPGGSLRL SCAASGRFTS YNPMGWFRQA PGKGRELVA 50
ISRTGGSTYY PDSVEGRFTI SRDPAKRMVY LQMNSLRAED TAVYYCAAAG 100
VRAEDGRVTR LPSEYTFWQG GTQVTVSSAA AEVQLVESGG GLVQPGGSLR 150
LSCAASGRFT SYNPMGWFRQ APKGRELVA AISRTGGSTY YPDSVEGRFT 200
ISRDPAKRMV YLQMNSLRAE DTAVYYCAA GVRADGRVR TLPSEYTFW 250
QGTQVTVSS 259
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-chain 22-96 153-227

cerlapirdinum

cerlapirdine


N,N-dimethyl-3-[[3-(naphthalene-1-sulfonyl)-1*H*-indazol-5-yl]oxy]propan-1-amine

cerlapirdine

N,N-diméthyl-3-[[3-(naphtalène-1-sulfonyl)-1*H*-indazol-5-yl]oxy]propan-1-amine

cerlapirdina

N,N-dimetil-3-[[3-(naftaleno-1-sulfonyl)-1*H*-indazol-5-il]oxi]propan-1-amina

C₂₂H₂₃N₃O₃S**dexmecamylaminum**

dexmecamylamine


(1*R*,2*S*,4*S*)-*N*,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine

dexamécamylamine

(1*R*,2*S*,4*S*)-*N*,2,3,3-tétraméthylbicyclo[2.2.1]heptan-2-amine

dexmecamilamina

(1*R*,2*S*,4*S*)-*N*,2,3,3-tetrametilbicio[2.2.1]heptan-2-amina



drisapersenum
drisapersen

all-P-ambo-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thiocytidylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioguanilyl-(3'→5')-2'-O-methyl-P-thioguanilyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thioguanilyl-(3'→5')-2'-O-methyl-P-thioguanilyl-(3'→5')-2'-O-methyl-P-thiocytidylyl-(3'→5')-2'-O-methyl-P-thiocytidylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thiocytidylyl-(3'→5')-2'-O-methyluridine

drisapersen

tout-P-ambo-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thiocytidylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioguanilyl-(3'→5')-2'-O-méthyl-P-thioguanilyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioguanilyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thioguanilyl-(3'→5')-2'-O-méthyl-P-thiocytidylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thiocytidylyl-(3'→5')-2'-O-méthyluridine

drisapersén

todo-P-ambo-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tiocitidilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tiocitidilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tiocitidilil-(3'→5')-2'-O-metiluridina

C₂₁₁H₂₇₅N₇₆O₁₁₉P₁₉S₁₉

(3'-5')(P-thio)(Um-Cm-Am-Am-Gm-Gm-Am-Am-Gm-Am-Um-Gm-Gm-Cm-Am-Um-Um-Um-Cm-Um)

faldaprevirum
faldaprevir


(1*R*,2*S*)-1-[[[2*S*,4*R*)-4-[[8-bromo-7-methoxy-2-[2-(2-methylpropanamido)-1,3-thiazol-4-yl]quinolin-4-yl]oxy]-1-[[2*S*)-2-[(cyclopentyloxy)carbonyl]amino]-3,3-dimethylbutanoyl]pyrrolidine-2-carboxamido]-2-ethenylcyclopropane-1-carboxylic acid

faldaprévir

acide (1*R*,2*S*)-1-[[[(2*S*,4*R*)-4-[[8-bromo-7-méthoxy-2-[2-(2-méthylpropanamido)-1,3-thiazol-4-yl]quinoléin-4-yl]oxy]-1-[(2*S*)-2-[[[(cyclopentylloxy)carbonyl]amino]-3,3-diméthylbutanoyl]pyrrolidine-2-carboxamido]-2-éthénylcyclopropane-1-carboxylique

faldaprevir

ácido (1*R*,2*S*)-1-[[[(2*S*,4*R*)-4-[[8-bromo-7-methoxy-2-[2-(2-metilpropanamido)-1,3-tiazol-4-il]quinolin-4-il]oxi]-1-[(2*S*)-2-[[[(ciclopentiloxi)carbonil]amino]-3,3-dimetilbutanoil]pirrolidina-2-carboxamido]-2-etenilciclopropano-1-carboxílico

C₄₀H₄₉BrN₆O₉S

flanvotumabum #
flanvotumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* TYRP1 (tyrosinase-related protein 1, 5,6-dihydroxyindole-2-carboxylic acid oxidase, DHICA oxidase, TRP1, melanoma antigen gp75)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV7-4-1*02 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; (228-228":231-231")-bisdisulfide dimer

flanvotumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* TYRP1 (protéine 1 apparentée à la tyrosinase, oxydase de l'acide 5,6-dihydroxyindole-2-carboxylique, DHICA-oxydase, TRP1, antigène gp75 du mélanome)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV7-4-1*02 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dimère (228-228":231-231")-bisdisulfure

flanvotumab

immunoglobulina G1-kappa, anti-[TYRP1 de *Homo sapiens* (proteína 1 relacionada con la tirosinasa), oxidasa del ácido 5,6-dihidroxiindol-2-carboxílico, DHICA-oxidasa, TRP1, antígeno gp75 de melanoma)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV7-4-1*02 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dímero (228-228":231-231")-bisdisulfuro


	<div>Heavy chain / Chaîne lourde / Cadena pesada</div> <div>QVQLVQSGSE LKKPGASVKI SCKASGYTFT SYAMNWVRQA PGQGLESMGW 50</div> <div>INTNTGNPTY AQGFTGRFVF SMDTSVSTAY LQISSSLKAED TAIYYCAPRY 100</div> <div>SSSWYLDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150</div> <div>YFPEPVTVSW NSGALTSGVH TFFAVLQSSG LYSLSSSVTV PSSSLGTQTY 200</div> <div>ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250</div> <div>DTLMISRTPF VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREQYNS 300</div> <div>TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350</div> <div>YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400</div> <div>DSDGSFFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449</div> <div>Light chain / Chaîne légère / Cadena ligera</div> <div>EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD 50</div> <div>ASNRATGIPA RFGSGSGSTD FTLTISSELP EDFAVYYCQQ RSNWLMYTFG 100</div> <div>QGKLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150</div> <div>VDNALQSGNS QESVTEQDSK DSTYLSSTL TLSKADYEKH KVICEVTHQ 200</div> <div>GLSSPVTKSF NRGEK 215</div> <div>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</div> <div>Intra-H 22-96 146-202 263-323 369-427</div> <div>22"-96" 146"-202" 263"-323" 369"-427"</div> <div>Intra-L 23"-88" 135"-195"</div> <div>23"-88" 135"-195"</div> <div>Inter-H-L 222-215' 222"-215"</div> <div>Inter-H-H 228-228" 231-231"</div> <div>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación</div> <div>299, 299"</div>
<div><div>follitropinum gamma #</div><div>follitropin gamma</div></div>	<div>heterodimer of human glycoprotein hormones alpha chain and</div> <div>follitropin subunit beta (FSH-beta), follicle stimulating hormone,</div> <div>glycoform gamma</div>
<div><div>follitropine gamma</div></div>	<div>hétérodimère constitué de la chaîne alpha des hormones</div> <div>glycoprotéiques et de la sous-unité bêta de la follitropine (FSH-bêta)</div> <div>humaines, hormone folliculostimulante, forme glycosylée gamma</div>
<div><div>follitropina gamma</div></div>	<div>heterodímero formado por la cadena alfa de las hormonas</div> <div>glicoprotéicas y la subunidad beta de la folitropina (FSH-beta)</div> <div>humanas, hormona estimulante del folículo, forma glicosilada</div> <div>gamma</div>
	<div>C₉₇₅H₁₄₉₃N₂₆₇O₃₀₅S₂₆ (peptide)</div> <div>Alpha subunit / Sous-unité alpha / Subunidad alfa</div> <div>APDVQDCPEC TLQENPFPSQ PGAPILQCMG CCFSTRAYPTP LRSKKTMLVQ 50</div> <div>KNVTSESTCC VAKSYNRVTV MGGFKVENHT ACHCSTCYH KS 92</div> <div>Beta subunit / Sous-unité bêta / Subunidad beta</div> <div>NSCELTNITI ALEKEECRFC ISINTWCAG YCYTRDLVYK DPARPKIQKT 50'</div> <div>CTFKELVYET VRVPGCAHHA DSLTYFPVAT QCHCGKCDSD STDCTVRGLG 100'</div> <div>PSYCSFGEMK E 111'</div> <div>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</div> <div>7-31 10-60 28-82 32-84 59-87</div> <div>3'-51' 17'-66' 20'-104' 28'-82' 32'-84' 87'-94'</div> <div>Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)</div> <div>Asn-7' Asn-24' Asn-52 Asn-78</div> <div><div><div><div><div>R6→6-</div><div>R3→3-β-Gal→4-β-Gl-N→2-</div></div><div><div>R4→4-</div><div>R3→3-β-Gal→4-β-Gl-N→2-</div></div></div><div><div>α-Man→6-</div><div>α-Man→3-</div></div><div><div>β-Man→4-β-Gl-N→4-</div></div><div><div>R→6-</div><div>β-Gl-N→N</div></div></div></div> <div>R = α-Fuc or H, R3 = α-Sia or H, R4 and R6 = R3→3-β-Gal→4-β-Gl-N or H</div>

gemcitabini elaidas

gemcitabine elaidate

élaïdate de gemcitabine

elaidato de gemcitabina

2'-deoxy-2',2'-difluorocytidine 5'-(9*E*)-octadec-9-enoate5'-(9*E*)-octadéc-9-énoate de 2'-déoxy-2',2'-difluorocytidine5'-(9*E*)-octadec-9-enoato de 2'-desoxi-2',2'-difluorocitidina $C_{27}H_{43}F_2N_3O_5$ **glyceroli phenylbutyras**

glycerol phenylbutyrate


phénylbutyrate de glycérol

fenilbutirato de glicerol

propane-1,2,3-triyl tris(4-phenylbutanoate)

tris(4-phénylbutanoate) de propane-1,2,3-triyle

tris(4-fenilbutanoato) de propano-1,2,3-triilo

 $C_{33}H_{38}O_6$ **idursulfasum beta #**

idursulfase beta

idursulfase bêta

idursulfasa beta

iduronate 2-sulfatase (α -L-iduronate sulfate sulfatase), human pro-enzyme produced in CHO cells (glycoform beta)iduronate 2-sulfatase (α -L-iduronate sulfate sulfatase), proenzyme humaine produite par des cellules CHO (glycoforme bêta)iduronato 2-sulfatasa (α -L-iduronato sulfato sulfatasa), proenzima humana producida por células CHO (forma glicosilada beta)

C₂₆₈₉H₄₀₅₁N₆₉₉O₇₉₃S₁₃


```

SETQANSTTD ALNVLLIIVD DLRPSLGCYG DKLVRSPNID QLASHSLLFQ 50
NAFAQQAVCA PSRVSF LTGR RPDTRRLYDF NSYWRVHAGN FSTIPQYFKE 100
NGYVTMSVGK VFHGGISSNH TDDSPYSWSF PPYHPSSEKY ENTKTCRGPD 150
GELHANLLCP VDVLDVPEGT LPDKQSTEQA IQLLEKMKTS ASPFFLAVGY 200
HKPHIFFRYP KEFQKLYPLE NITLAPDPEV PDGLPPVAYN PWMMDIQRED 250
VQALNISVPY GPIPVDFQRK TRQSYFASVS YLDTQVGRLL SALDDQLAN 300
STIIAFTSDH GWALGEHGEW AKYSNFDVAT HVPLIFYVPG RTASLPEAGE 350
KLFFYLDPFD SASQLMEPGR QSMDLVLELV LFPPTLAGLAG LQVPPRCVPF 400
SFHVELCREG KNLLKHFRFR DLEEDPYLPG NPRELIAYSQ YPRPSDIPQW 450
NSDKPSLKDI KIMGYSIRTI DYRYTVWVG F NPDEFLANFS DIHAGELYFV 500
DSDPLQDHNM YNDSQGGDLF QLLMP 525

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
146-159 397-407

Modified residue / Résidu modifié / Residuo modificado



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-6 Asn-90 Asn-119 Asn-221 Asn-255 Asn-300 Asn-488 Asn-512

inlacumabum # inlacumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* SELP (selectin P, CD62)], *Homo sapiens* monoclonal antibody;
gamma4 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-13*01 (94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 hinge S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (230-230":233-233")-bisdisulfide dimer

inlacumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* SELP (sélectine P, CD62)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma4 (1-451) [*Homo sapiens* VH (IGHV3-13*01 (94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 charnière S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (230-230":233-233")-bisdisulfure

inlacumab

immunoglobulina G4-kappa, anti-[SELP de *Homo sapiens* (selectina P, CD62)], anticuerpo monoclonal de *Homo sapiens* ;
cadena pesada gamma4 (1-451) [*Homo sapiens* VH (IGHV3-13*01 (94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 bisagra S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (230-230":233-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada			
EVQLVESGGG	LVRPGGSLRL	SCAASGFTFS	NYDMHWVRQA
ITAAAGDIYYP	GSVKGRFTIS	RENAKNSLYL	QMNSLRAGDT
SGSGSYNDW	FDFWGGQTLV	TVSSASTKGP	SVFPLAPCSR
CLVKDYFPEP	VTVSWNSGAL	TSGVHTFPAV	LQSSGLYSL
GTKTYTCNVD	HKPSNTKVDK	RVESKYGPPC	PCCPAPEFEG
PKDTLMISRT	PEVTCVVVDV	SQEDPEVQFN	WYVDGVEVHN
NSTYRVVSVL	TVLHQDWLNG	KEYKCKVSNK	GLPSSIEKTI
QVYTLPPSQE	EMTKNQVSLT	CLVKGFPYPSD	IAVEWESNGQ
VLDSDGGSFFL	YSRLTVDKSR	WQEGNVFSCS	VMHEALHNHY
K			
Light chain / Chaîne légère / Cadena ligera			
EIVLTQSPAT	LSLSPGERAT	LSCRASQSVS	SYLAWYQQKP
ASNRATGIPA	RFSGSGSGTD	FTLTISSELP	EDFAVYYCQQ
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY
DNALQSGNSQ	ESVTEQDSKD	STYLSLSLT	LSKADYEKHK
LSPFVTKSFN	RGEC		
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro			
Intra-H	22-95	151-207	265-325
Intra-L	23'-88'	134'-194'	
Inter-H-L	138-214'	138"-214"	
Inter-H-H	230-230"	233-233"	
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación			
301, 301"			

lucerastatum
lucerastat


(2*R*,3*S*,4*R*,5*S*)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol

lucérastat

(2*R*,3*S*,4*R*,5*S*)-1-butyl-2-(hydroxyméthyl)pipéridine-3,4,5-triol

lucerastat

(2*R*,3*S*,4*R*,5*S*)-1-butil-2-(hidroximetil)piperidina-3,4,5-triol



naltalimidum
naltalimide



2-[17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6β-yl]isoindole-1,3-dione

naltalimide

2-[17-(cyclopropylméthyl)-4,5α-époxy-3,14-dihydroxymorphinan-6β-yl]-2*H*-isoindole-1,3-dione

naltalimida

2-[17-(ciclopropilmetil)-4,5α-epoxi-3,14-dihidroximorfinan-6β-il]isoindol-1,3-diona



netazepidum
netazepide



1-[(3*R*)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1*H*-1,4-benzodiazepin-3-yl]-3-[3-(methylamino)phenyl]urea

nétazépide

1-[(3*R*)-1-(3,3-diméthyl-2-oxobutyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1*H*-1,4-benzodiazépin-3-yl]-3-[3-(méthylamino)phényl]urée

netazepida

1-[(3*R*)-1-(3,3-dimetil-2-oxobutil)-2-oxo-5-(piridin-2-il)-2,3-dihydro-1*H*-1,4-benzodiazepin-3-il]-3-[3-(metilamino)fenil]urea



niraparibum
niraparib



2-[4-[(3*S*)-piperidin-3-yl]phenyl]-2*H*-indazole-7-carboxamide

niraparib

2-[4-[(3*S*)-pipéridin-3-yl]phényl]-2*H*-indazole-7-carboxamide

niraparib

2-[4-[(3*S*)-piperidin-3-il]fenil]-2*H*-indazol-7-carboxamida



ondelopranum

ondelopran


6-[2-fluoro-4-({[2-(oxan-4-yl)ethyl]amino}methyl)phenoxy]pyridine-3-carboxamide

ondélopran

6-[2-fluoro-4-({[2-(oxan-4-yl)éthyl]amino}méthyl)phénoxy]pyridine-3-carboxamide

ondeloprán

6-[2-fluoro-4-({[2-(oxan-4-il)etil]amino}metil)fenoxi]piridina-3-carboxamida

 $C_{20}H_{24}FN_3O_3$ **patiomerum calcium**

patiomer calcium


cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene

patiromère calcique

polymère réticulé de 2-fluoroprop-2-énoate de calcium avec du diéthénylbencène et de l'octa-1,7-diène

patirómero cálcico

polímero reticulado de 2-fluoroprop-2-enoato de calcio con dietenilbenceno y octa-1,7-dieno

 $[[C_3H_2FO_2)_2 Ca]_9 [C_8H_{14}] [C_{10}H_{10}]]_n$ **patritumabum #**

patritumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3)], *Homo sapiens* monoclonal antibody;
 gamma1 heavy chain (1-447) [*Homo sapiens* VH (IGHV4-34*01 (99.00%) - (IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)], (220-220')-disulfide with kappa light chain (1'-220') [*Homo sapiens* V-KAPPA (IGKV4-1*01 (95.00%) -IGKJ1*01) [12.3.9] (1'-113') -IGKC*01 (114'-220')]; (226-226'':229-229'')-bisdisulfide dimer

patritumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* ERBB3 (récepteur tyrosine-protéine kinase erbB3, HER3)], *Homo sapiens* anticorps monoclonal;
 chaîne lourde gamma1 (1-447) [*Homo sapiens* VH (IGHV4-34*01 (99.00%) - (IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)], (220-220')-disulfure avec la chaîne légère kappa (1'-220') [*Homo sapiens* V-KAPPA (IGKV4-1*01 (95.00%) -IGKJ1*01) [12.3.9] (1'-113') -IGKC*01 (114'-220')]; dimère (226-226'':229-229'')-bisdisulfure

patritumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* ERBB3 (receptor de tirosina-proteína quinasa erbB3, HER3)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-447) [*Homo sapiens* VH (IGHV4-34*01 (99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117)-IGHG1*03 (118-447)], (220-220')-disulfuro con la cadena ligera kappa (1'-220') [*Homo sapiens* V-KAPPA (IGKV4-1*01 (95.00%) -IGKJ1*01) [12.3.9] (1'-113') -IGKC*01 (114'-220')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQWGAG LLKPSETLSL TCAVYGGSF S GYWSWIRQP PGKGLEWIGE 50
INHSGSTNYN PSLKSRVTIS VETSKNQFSL KLSSVTAADT AVYYCARDKW 100
TWYFDLWGRG TLTVTSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTGPS SSLGTQTYIC 200
NVNHKPSNTK VDKRVEPKSC DKHTCPCPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK FREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTIKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPVLD 400
DGSFPLYSKL TVDKSRWQGG NVFSCSVME ALHNHYTQKS LSLSPGK 447
```

Light chain / Chaîne légère / Cadena ligera

```
DIEMTQSPDS LAVSLGERAT INCRSSQSVL YSSSNRNYLA WYQNPQGP 50
KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQYYST 100
PRTFGQGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNFPYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSITYS LSSTLTLSKA DYEKKHKVAC 200
EVTHQGLSSP VTKSFNRGEC 220
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22'-95" 144'-200" 261'-321" 367'-425"
22"-95" 144"-200" 261"-321" 367"-425"
Intra-L 23'-94" 140'-200"
23"-94" 140"-200"
Inter-H-L 220'-220" 220"-220"
Inter-H-H 226'-226" 229'-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

297, 297"

plazomicinum

plazomicin


(2*S*)-4-amino-*N*-[(1*R*,2*S*,3*S*,4*R*,5*S*)-5-amino-4-[[[(2*S*,3*R*)-3-amino-6-[[[(2-hydroxyethyl)amino]methyl]-3,4-dihydro-2*H*-pyran-2-yl]oxy]-2-[[[3-deoxy-4-*C*-methyl-3-(methylamino)-β-*L*-arabinopyranosyl]oxy]-3-hydroxycyclohexyl]-2-hydroxybutanamide

plazomicine

(2*S*)-4-amino-*N*-[(1*R*,2*S*,3*S*,4*R*,5*S*)-5-amino-4-[[[(2*S*,3*R*)-3-amino-6-[[[(2-hydroxyéthyl)amino]méthyl]-3,4-dihydro-2*H*-pyran-2-yl]oxy]-2-[[[3-déoxy-4-*C*-méthyl-3-(méthylamino)-β-*L*-arabinopyranosyl]oxy]-3-hydroxycyclohexyl]-2-hydroxybutanamide

plazomicina

(2*S*)-4-amino-*N*-[(1*R*,2*S*,3*S*,4*R*,5*S*)-5-amino-4-[[[(2*S*,3*R*)-3-amino-6-[[[(2-hidroxietil)amino]metil]-3,4-dihidro-2*H*-piran-2-il]oxi]-2-[[[3-desoxi-4-*C*-metil-3-(metilamino)-β-*L*-arabinopiranosil]oxi]-3-hidroxiciclohexil]-2-hidroxibutanamida


C₂₅H₄₈N₆O₁₀

pradigastatum


pradigastat

{{(1*r*,4*r*)-4-[4-(5-[[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl)phenyl]cyclohexyl}acetic acid

pradigastat	acide { <i>trans</i> -4-[4-(5-{[6-(trifluorométhyl)pyridin-3-yl]amino}pyridin-2-yl)phényl]cyclohexyl}acétique
pradigastat	ácido {(1 <i>r</i> ,4 <i>r</i>)-4-[4-(5-{[6-(trifluorometil)piridin-3-il]amino}piridin-2-il)fenil]ciclohexil}acético

C₂₅H₂₄F₃N₃O₂

pritelivirum pritelivir	<i>N</i> -methyl- <i>N</i> -(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-2-yl)phenyl]acetamide
pritélivir	<i>N</i> -méthyl- <i>N</i> -(4-méthyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-2-yl)phényl]acétamide
pritelivir	<i>N</i> -metil- <i>N</i> -(4-metil-5-sulfamoil-1,3-tiazol-2-il)-2-[4-(pyridin-2-il)fenil]acetamida

C₁₈H₁₈N₄O₃S₂

quilizumabum # quilizumab	immunoglobulin G1-kappa, anti-[<i>Homo sapiens</i> IGHE connecting region (CO) M1 prime (in alternatively spliced heavy chain of membrane IgE on B cells)], humanized monoclonal antibody; gamma1 heavy chain (1-447) [humanized VH (<i>Homo sapiens</i> IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1-117) - <i>Homo sapiens</i> IGHG1*03 CH1 R120>K (214) (118-447)], (220-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') - <i>Homo sapiens</i> IGKC*01 (113'-219')]; (226-226":229-229")-bisdisulfide dimer
quilizumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> IGHE région de connexion (CO) M1 prime (dans la chaîne lourde des IgE membranaires à la surface des lymphocytes B, épissée de manière alternative)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-447) [VH humanisé (<i>Homo sapiens</i> IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1-117) - <i>Homo sapiens</i> IGHG1*03 CH1 R120>K (214) (118-447)], (220-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') - <i>Homo sapiens</i> IGKC*01 (113'-219')]; dimère (226-226":229-229")-bisdisulfure

quilizumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IGHE región de conexión (CO) M1 prime (en la cadena pesada de las IgE de membrana de la superficie de los linfocitos B, ensamblada de modo alternativo)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 CH1 R120>K (214) (118-447)], (220-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG	LVQPGGSLRL	SCAASGFTFS	DYGIWVRQA	PGKGLEWVAF	50
ISDLYATIIY	ADITVTRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCARDN	100
WDAMDYWGQG	TLVTVSSAST	KGPSVFPPLAP	SSKSTSGGTA	ALGCLVKDYF	150
PEPVTVSWNS	GALTSGVHTF	PAVLQSSGLY	SLSSVVTVP	SSLGTQTYIC	200
NVNHKPSNTK	VDKKVEPKSC	DKTHTCPPCP	APELLGGPSV	FLFPPKPKDT	250
LMISRTPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY	300
RVVSVLTIVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK	GQPREPQVYT	350
LPPSREEMTK	NQVSLTCLVK	GFYPDSIAVE	WESNGQPENN	YKTTTPPVLD	400
DGSFFLYSKL	TVDKSRWQGG	NVFSCSVME	ALHNHYTQKS	LSLSFGK	447

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS	LSASVGDRVT	ITCRSSQSLV	HNNANTYLHW	YQQKPGKAPK	50
LLIYKVSINRF	SGVPSRFRSG	GSCTDFTLTI	SSLQPEDFAT	YYCSQNTLVP	100
WTFGQGTKVE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK	150
VQWKVDNALQ	SGNSQESVTE	QDSKDSITYSL	SSTLTLSKAD	YEKHKVYACE	200
VTHQGLSSPV	TKSFNRGEC				219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 144-200 261-321 367-425
22"-96" 144"-200" 261"-321" 367"-425"



Intra-L 23'-93' 139'-199'
23'''-93''' 139'''-199'''

Inter-H-L 220-219' 220"-219"

Inter-H-H 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
297, 297" (non-fucosylated oligosaccharides)radavirsenum
radavirsen

all-P-ambo-P,2',3'-trideoxy-P-(dimethylamino)-5'-O-{P-[4-({2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}carbonyl)piperazin-1-yl]-N,N-dimethylphosphonamidoyl}-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secocytidyl-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanlyl-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanlyl-(2'a→5')-P,3'-dideoxy-P-(piperazin-1-yl)-2',3'-imino-2',3'-secothymidyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secothymidyl-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoadenyl-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanlyl-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoadenyl-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanlyl-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoadenyl-(2'a→5')-P,2',3'-trideoxy-P-(piperazin-1-yl)-2',3'-imino-2',3'-secocytidyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secothymidyl-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secocytidyl-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoadenyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secothymidyl-(2'a→5')-P,2',3'-trideoxy-P-(piperazin-1-yl)-2',3'-imino-2',3'-secocytidyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secothymidyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secothymidyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secothymidine



B(1-20) : C-G-G-T-T-A-G-A-A-G-A-C-T-C-A-T-C-T-T-T

R(1-3) = R(5-11) = R(13-16) = R(18) = R(19) = -N(CH₃)₂

R(4) = R(12) = R(17) = HN—

rafigrelidum
rafigrelide



6,7-dichloro-3,3-dimethyl-5,10-dihydroimidazo[2,1-*b*]quinazolin-2(3*H*)-one

rafigrélide

6,7-dichloro-3,3-diméthyl-1,5-dihydroimidazo[2,1-*b*]quinazolin-2(3*H*)-one

rafigrelida

6,7-dicloro-3,3-dimetil-5,10-dihidroimidazo[2,1-*b*]quinazolin-2(3*H*)-ona



refametinibum
refametinib



N-(3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl)-1-[(2*S*)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide

réfamétinib

N-(3,4-difluoro-2-[(2-fluoro-4-iodophényl)amino]-6-méthoxyphényl)-1-[(2*S*)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide

refametinib

N-(3,4-difluoro-2-[(2-fluoro-4-iodofenil)amino]-6-metoxifenil)-1-[(2*S*)-2,3-dihidroxiopropil]ciclopropano-1-sulfonamida



rigosertibum

rigosertib


N-[2-methoxy-5-({[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl)methyl}phenyl]glycine

rigosertib

N-[2-méthoxy-5-({[(1E)-2-(2,4,6-triméthoxyphényl)éthényl]sulfonyl)méthyl}phényl]glycine

rigosertib

N-[2-metoxi-5-({[(1E)-2-(2,4,6-trimetoxifenil)etenil]sulfonyl)metil}fenil]glicina

C₂₁H₂₅NO₈S**riodipinum**

riodipine


dimethyl 4-[2-(difluoromethoxy)phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

riodipine

4-[2-(difluorométhoxy)phényl]-2,6-diméthyl-1,4-dihydropyridine-3,5-dicarboxylate de diméthyle

riodipino

4-[2-(difluorometoxi)fenil]-2,6-dimetil-1,4-dihidropiridina-3,5-dicarboxilato de dimetilo

C₁₈H₁₉F₂NO₅**romosozumabum #**

romosozumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* SOST (sclerostin)], humanized monoclonal antibody;
 gamma2 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV1-2*02 (87.80%) -(IGHD)-IGHJ2*01 R120>Q (115), L123>T (118) [8.8.16] (1-123) -*Homo sapiens* IGHG2*01 (124-449)], (137-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (89.50%) -IGKJ4*02 [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214'))]; (225-225'':226-226'':229-229'':232-232'')-tetrakisdisulfide dimer

romosozumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* SOST (sclérostine)], anticorps monoclonal humanisé;
 chaîne lourde gamma2 (1-449) [VH humanisé (*Homo sapiens* IGHV1-2*02 (87.80%) -(IGHD)-IGHJ2*01 R120>Q (115), L123>T (118) [8.8.16] (1-123) -*Homo sapiens* IGHG2*01 (124-449)], (137-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-33*01 (89.50%) -IGKJ4*02 [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214'))]; dimère (225-225'':226-226'':229-229'':232-232'')-tétrakisdisulfure

romosozumab

inmunoglobulina G2-kappa, anti-[SOST (esclerostina) de *Homo sapiens*], anticuerpo monoclonal humanizado;
cadena pesada gamma2 (1-449) [VH humanizado (*Homo sapiens*IGHV1-2*02 (87.80%) -(IGHD)-IGHJ2*01 R120>Q (115), L123>T (118) [8.8.16] (1-123) -*Homo sapiens*IGHG2*01 (124-449)], (137-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens*IGKV1-33*01 (89.50%) -IGKJ4*02) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dímero (225-225":226-226":229-229":232-232")-tetraquisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGASVKV SCKASGYTFT DYNMHWVRQA PGQGLEWMGE 50
INPNSGGAGY NQKFKGRVTM TTDTSSTAY MELRSLRSD TAVYYCARLG 100
YDDIYDDWYF DVWGQGTTVT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFFPAVL QSSGLYSLS VVTVPSSNFG 200
TQYTYCNVDH KPSNTKVDKT VERKCCVECP PCPAPPVAGP SVFLFPFKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TFRVSVSLTV VHQDWLNGKE YKCKVSNKGL PAPIEKTISK TKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPML 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCVM HEALHNHYTQ KSLSLSPGK 449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQDIS NYLNWYQQKPK GKAPKLLIYY 50
TSRLLSGVPS RFSGSGSGTD FTLTISLQP EDFATYYCQQ GDTLPYTFGG 100
GTRKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKKH VYACEVTHQG 200
LSSPVTKSFN RGEC 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 150-206 263-323 369-427
22"-96" 150"-206" 263"-323" 369"-427"
Intra-L 23'-88' 134'-194'
23"-88" 134"-194"
Inter-H-L 137-214' 137"-214"
Inter-H-H 225-225" 226-226" 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299"

samidorphanum

samidorphan


17-(cyclopropylmethyl)-4,14-dihydroxy-6-oxomorphinan-3-carboxamide

samidorphan

17-(cyclopropylméthyl)-4,14-dihydroxy-6-oxomorphinane-3-carboxamide

samidorfano

17-(ciclopropilmetil)-4,14-dihidroxi-6-oxomorfinan-3-carboxamida

C₂₁H₂₆N₂O₄

sapitinibum

sapitinib


2-[4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)piperidin-1-yl]-N-methylacetamide

sapitinib

2-[4-({4-[(3-chloro-2-fluorophényl)amino]-7-méthoxyquinazolin-6-yl}oxy)pipéridin-1-yl]-N-méthylacétamide

sapatinib

2-[4-({4-[(3-cloro-2-fluorofenil)amino]-7-metoxiquinazolin-6-il)oxi)piperidin-1-il]-N-metilacetamida

C₂₃H₂₅ClFN₅O₃

sarilumabum #

sarilumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL6R (interleukin 6 receptor, IL-6R, CD126)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-446) [*Homo sapiens* VH (IGHV3-9*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)], (219-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (225-225'':228-228'')-bisdisulfide dimer

sarilumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL6R (récepteur de l'interleukine 6, IL-6R, CD126)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-446) [*Homo sapiens* VH (IGHV3-9*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)], (219-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (225-225'':228-228'')-bisdisulfure

sarilumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL6R (receptor de la interleukina 6, IL-6R, CD126)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-446) [*Homo sapiens* VH (IGHV3-9*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (225-225'':228-228'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG	LVQPGRSRLRL	SCAASRFTFD	DYAMHWVRQA	PGKLEWVSG	50
ISWNSGRIGY	ADSVKGRFTI	SRDNAENSLF	LQMNGLRAED	TALYYCAKGR	100
DSFDIWGGQT	MVTVSSASTK	GPSVFPLAPS	SKSTSGGTAA	LGCLVKDYFP	150
EPVTVSWNSG	ALTSGVHTFP	AVLQSSGLYS	LSSVVTVPSS	SLGTQTYICN	200
VNHKPSNTKV	DKKVEPKSCD	KHTCTPCPCA	PELLGGPSVF	LFPPKPKDTL	250
MISRTPEVTC	VVVDVSHEDP	EVKFNWYVDG	VEVHNAKTKP	REEQYNSTYR	300
VVSVLTVLHQ	DWLNGKEYKC	KVSNKALPAP	IEKTISKAKG	QPREPQVYTL	350
PPSRDELTKN	QVSLTCLVKG	FYPSPDIAVEW	ESNGQPENNY	KTTTPPVLDSD	400
GSFFLYSKLT	VDKSRWQQGN	VFSCSVMHEA	LHNHYTQKSL	SLSPGK	446

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS	VSASVGDRVT	ITCRASQGIS	SWLAWYQQKP	GKAPKLLIYG	50
ASSLESGVPS	RFGSGSGSDT	FTLTISSLQP	EDFASYQCQ	ANSFPYTFQG	100
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLNNFY	PREAKVQWKV	150
DNALQSGNSQ	ESVTEQDSKD	STYSLSTLT	LSKADYERHK	VYACEVTHQG	200
LSSPVTKSFN	RGEC				214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	143-199	260-320	366-424
	22"-96"	143"-199"	260"-320"	366"-424"
Intra-L	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L	219-214'	219"-214'"		
Inter-H-H	225-225"	228-228"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

296, 296"

secretinum humanum

secretin human

human peptide hormone secretin;
 L-histidyl-L-seryl-L-aspartylglycyl-L-threonyl-L-phenylalanyl-
 L-threonyl-L-seryl-L-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucyl-
 L-arginyl-L-glutamylglycyl-L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-
 L-arginyl-L-leucyl-L-leucyl-L-glutamylglycyl-L-leucyl-L-valinamide

sécrétine humaine

sécrétine humaine hormone peptidique;
 L-histidyl-L-séryl-L-aspartylglycyl-L-thréonyl-L-phénylalanil-
 L-thréonyl-L-séryl-L-glutamyl-L-leucyl-L-séryl-L-arginyl-L-leucyl-
 L-arginyl-L-glutamylglycyl-L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-
 L-arginyl-L-leucyl-L-leucyl-L-glutamylglycyl-L-leucyl-L-valinamide


secretina humana

secretina humana, hormona peptídica;
 L-histidil-L-seril-L-aspartilglicil-L-treonil-L-fenilalanil-L-treonil-L-seril-
 L-glutamil-L-leucil-L-seril-L-arginil-L-leucil-L-arginil-L-glutamilglicil-
 L-alanil-L-arginil-L-leucil-L-glutaminil-L-arginil-L-leucil-L-leucil-
 L-glutaminilglicil-L-leucil-L-valinamida

C₁₃₀ H₂₂₀ N₄₄ O₄₀

HSDGTFTSEL SRLREGARLQ RLLQGLV 27

Modified residue / Résidu modifié / Residuo modificado

**selisistatum**


selisistat

rac-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazole-1-carboxamide

sélisistat

rac-6-chloro-2,3,4,9-tétrahydro-1*H*-carbazole-1-carboxamide

selisistat

rac-6-cloro-2,3,4,9-tetrahidro-1*H*-carbazol-1-carboxamidaC₁₃H₁₃ClN₂O**setrobuvirum**

setrobuvir


N-(3-((4*aR*,5*S*,8*R*,8*aS*)-1-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2,4*a*,5,6,7,8,8*a*-octahydro-5,8-methanoquinolin-3-yl)-1,1-dioxo-1,4-dihydro-1*λ*⁶,2,4-benzothiadiazin-7-yl)methanesulfonamide

sétrobuvir

N-(3-((4*aR*,5*S*,8*R*,8*aS*)-1-[(4-fluorophényl)méthyl]-4-hydroxy-2-oxo-1,2,4*a*,5,6,7,8,8*a*-octahydro-5,8-méthanoquinoléin-3-yl)-1,1-dioxo-1,4-dihydro-1*λ*⁶,2,4-benzothiadiazin-7-yl)méthanesulfonamide

setrobuvir

N-(3-((4*aR*,5*S*,8*R*,8*aS*)-1-[(4-fluorofenil)metil]-4-hidroxi-2-oxo-1,2,4*a*,5,6,7,8,8*a*-octahidro-5,8-metanoquinolin-3-il)-1,1-dioxo-1,4-dihidro-1*λ*⁶,2,4-benzotiadiazin-7-il)metanosulfonamida



sevuparinum natricum
sevuparin sodium

sodium salt of a low molecular mass heparin obtained by depolymerization through periodate oxidation of heparin from porcine intestinal mucosa, followed by reduction and mild acid hydrolysis of the product; the majority of the components have a 2-amino-2-deoxy-D-glucopyranose derivative structure at both ends of their chain, the one at the reducing end can be substituted with threonic acid or erythronic acid; the relative average molecular mass range is approximately 7,500 daltons with about 90% ranging between 2,000 and 15,000 daltons; the degree of sulfation is 2 to 2.5 per disaccharidic unit

sévuparine sodique

sel sodique d'une héparine de basse masse moléculaire obtenue par dépolymérisation, au moyen d'une oxydation périodique, d'héparine de muqueuse intestinale de porc, suivi par une réduction et par une hydrolyse douce; la majorité des composants de la sévuparine sodique possèdent une structure 2-amino-2-déoxy-D-glucopyranose aux deux extrémités, la réductrice peut être substituée par un acide thréonique ou érythronique; la masse moléculaire relative moyenne est approximativement de 7500 daltons, et celles de 90% sont comprises entre 2000 à 15000; le degré de sulfatation est de 2 à 2,5 par unité disaccharide.

sevuparina sódica

sal sódica de una heparina de baja masa molecular obtenida por despolimerización, mediante oxidación periódica, de heparina de mucosa intestinal porcina, seguida de reducción e hidrólisis con ácido débil; la mayoría de los componentes de la sevuparina sódica tienen una estructura 2-amino-2-desoxi-D-glucopiranososa en los dos extremos, el reductor puede estar substituido con un ácido treónico o eritrónico; la masa molecular relativa media es aproximadamente de 7500 dalton, y con el 90% comprendido entre 2000 y 15000; el grado de sulfatación es de 2 a 2,5 por unidad de disacárido

solitomabum #
solitomab

immunoglobulin scFv-scFv, anti-[*Homo sapiens* EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, KSA, KS1/4 antigen, M4S1, tumor antigen 17-1A, Ep-CAM, EpCAM, CD326)]/anti-[*Homo sapiens* CD3E (CD3 epsilon)], *Mus musculus* monoclonal antibody bispecific single chain;
scFv anti-EPCAM [*Mus musculus* V-KAPPA (IGKV8-19*01 (98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer tris(tetraglycyl-seryl) linker (114-128) -*Mus musculus* VH (IGHV1-54*01 (85.90%)-IGHJ4*01, S123>T (243)) [8.8.14] (129-248)] -5-mer tetraglycyl-seryl linker (249-253) -scFv anti-CD3E [humanized VH (*Homo sapiens* IGHV1-46*01 (82.50%)-IGHJ6*01) [8.8.12] (254-372) -18-mer linker (373-390) -V-KAPPA (*Mus musculus* IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493) [5.3.9] (391-496)] -hexahistidine (497-502)

solitomab

immunoglobuline scFv-scFv, anti-[*Homo sapiens* EPCAM (molécule d'adhésion des cellules épithéliales, transducteur 1 du signal calcium associé aux tumeurs, TACSTD1, protéine 2 associée aux tumeurs gastrointestinales, GA733-2, glycoprotéine épithéliale 2, EGP-2, KSA, antigène KS1/4, M4S1, antigène tumoral 17-1A, Ep-CAM, EpCAM, CD326)]/anti-[*Homo sapiens* CD3E (CD3 epsilon)], *Mus musculus* anticorps monoclonal bispécifique à chaîne unique; scFv anti-EPCAM [*Mus musculus* V-KAPPA (IGKV8-19*01 (98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer tris(tétraglycyl-séryl) linker (114-128) -*Mus musculus* VH (IGHV1-54*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129-248)] -5-mer tétraglycyl-séryl linker (249-253) -scFv anti-CD3E [VH humanisé (*Homo sapiens* IGHV1-46*01 (82.50%)-(IGHD)-IGHJ6*01) [8.8.12] (254-372) -18-mer linker (373-390) -V-KAPPA (*Mus musculus* IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493) [5.3.9] (391-496)] -hexahistidine (497-502)

solitomab

immunoglobulina scFv-scFv, anti-[EPCAM de *Homo sapiens* (molécule de adhésion de células epiteliales, transductor 1 de la señal de calcio asociado a tumores, TACSTD1, proteína 2 asociada a tumores gastrointestinales, GA733-2, glicoproteína epitelial 2, EGP-2, KSA, antígeno KS1/4, M4S1, antígeno tumoral 17-1A, Ep-CAM, EpCAM, CD326)]/anti-[*Homo sapiens* CD3E (CD3 epsilon)], anticuerpo monoclonal biespecífico monocatenario de *Mus musculus*; scFv anti-EPCAM [*Mus musculus* V-KAPPA (IGKV8-19*01 (98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer tris(tetraglicil-seril) conector (114-128) -*Mus musculus* VH (IGHV1-54*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129-248)] -5-mer tetraglicil-seril conector (249-253) -scFv anti-CD3E [VH humanizado (*Homo sapiens* IGHV1-46*01 (82.50%)-(IGHD)-IGHJ6*01) [8.8.12] (254-372) -18-mer conector (373-390) -V-KAPPA (*Mus musculus* IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493) [5.3.9] (391-496)] -hexahistidina (497-502)

```
ELVMTQSPSS LTVTAGEKVT MSCKSSQSLN NSGNQKNYLT WYQKPGQPP 50
KLLIYWASTR ESGVPDRFTG SGSGTDFTLT ISSVQAEDLA VYYCNDYSY 100
PLTFGAGTKL EIKGGGGSGG GSGGGGSEV QLLEQSGAEL VRPGTSVKIS 150
CKASGYAFTN YLWGWVQRQ GHGLEWIGDI FPGSGNIHYN EKFKGKATLT 200
ADKSSSTAYM QLSSLTFFDS AVYFCARLRN WDEPMDYWGQ GTTIVTVSSGG 250
GGSDDVQLVQS GAEVKKPGAS VKVSCASGY TFTRYTMHWV RQAPGQGLEW 300
IGYINPSRGY TNYADSVKGR FTITTDKSTS TAYMELSSLR SEDTATYYCA 350
RYYDDHYCLD YWQGQTTVTV SSGEGTSTGS GSGGGSGGAD DIVLTQSPAT 400
LSLSPGERAT LSCRASQSVS YMNWYQQKPG KAPKRWIYDT SKVASGVPAR 450
FSGSGSGTDY SLTINSLEAE DAATYYCQQW SSNPLTFGGG TKVEIKHHHH 500
HH
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-chain 23-94 151-225 275-349 413-477

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
305 (but Pro in 306)

sovaprevirum
sovaprevir


(2*S*,4*R*)-1-[(2*S*)-2-*tert*-butyl-4-oxo-4-(piperidin-1-yl)butanoyl]-*N*-{[(1*R*,2*S*)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]pyrrolidine-2-carboxamide

sovaprévir

(2*S*,4*R*)-1-[(2*S*)-2-*tert*-butyl-4-oxo-4-(pipéridin-1-yl)butanoyl]-
N-{[(1*R*,2*S*)-1-[(cyclopropanesulfonyl)carbamoyl]-
 2-éthénylcyclopropyl]-4-[(7-méthoxy-2-phénylquinoléin-
 4-yl)oxy]pyrrolidine-2-carboxamide

sovaprevir

(2*S*,4*R*)-1-[(2*S*)-2-*tert*-butyl-4-oxo-4-(pipéridin-1-il)butanoil]-
N-{[(1*R*,2*S*)-1-[(ciclopropanosulfonyl)carbamoil]-2-etenilciclopropil]-
 4-[(7-metoxi-2-fenilquinolin-4-il)oxi]pirrolidina-2-carboxamida

C₄₃H₅₃N₅O₈S**sutezolidum**

sutezolid


N-({(5*S*)-3-[3-fluoro-4-(thiomorpholin-4-yl)phényl]-2-oxo-
 1,3-oxazolan-5-yl)méthyl}acetamide

sutézolid

N-({(5*S*)-3-[3-fluoro-4-(thiomorpholin-4-yl)phényl]-2-oxo-
 1,3-oxazolidin-5-yl)méthyl}acétamide

sutezolid

N-({(5*S*)-3-[3-fluoro-4-(tiomorfolin-4-il)fenil]-2-oxo-1,3-oxazolan-
 5-il)metil}acetamida

C₁₆H₂₀FN₃O₃S**tanzisertibum**

tanzisertib



(1*r*,4*r*)-4-({9-[(3*S*)-oxolan-3-yl]-8-[(2,4,6-trifluorophényl)amino]-
 9*H*-purin-2-yl}amino)cyclohexan-1-ol

tanzisertib

(1*r*,4*r*)-4-({9-[(3*S*)-oxolan-3-yl]-8-[(2,4,6-trifluorophényl)amino]-
 9*H*-purin-2-yl}amino)cyclohexan-1-ol

tanzisertib

(1*r*,4*r*)-4-({9-[(3*S*)-oxolan-3-il]-8-[(2,4,6-trifluorfenil)amino]-9*H*-purin-
 2-il}amino)ciclohexan-1-ol

**tavaborolum**



tavaborole

5-fluoro-2,1-benzoxaborol-1(3*H*)-ol

tavaborole

5-fluoro-2,1-benzoxaborol-1(3*H*)-ol

tavaborol

5-fluoro-2,1-benzoxaborol-1(3*H*)-ol**tedatioxetinum**

tedatioxetine


4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine

tedatioxétine

4-{2-[(4-méthylphényl)sulfanyl]phényl}pipéridine

tedatioxetina

4-{2-[(4-metilfenil)sulfanil]fenil}piperidina

**tipiracilum**



tipiracil

5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1*H*,3*H*)-dione

tipiracil

5-chloro-6-[(2-iminopyrrolidin-1-yl)méthyl]pyrimidine-2,4-(1*H*,3*H*)-dione

tipiracilo

5-cloro-6-[(2-iminopirrolidin-1-il)metil]pirimidina-2,4-(1*H*,3*H*)-diona

tirasemtivum


tirasemtiv

6-ethynyl-1-(pentan-3-yl)-2*H*-imidazo[4,5-*b*]pyrazin-2-one

tirasemtiv

6-éthynyl-1-(pentan-3-yl)-1,3-dihydro-2*H*-imidazo[4,5-*b*]pyrazin-2-one

tirasemtiv

6-etinil-1-(pentan-3-il)-2*H*-imidazo[4,5-*b*]pirazin-2-ona**tozadenantum**


tozadenant

4-hydroxy-*N*-[4-methoxy-7-(morpholin-4-yl)-1,3-benzothiazol-2-yl]-4-methylpiperidine-1-carboxamide

tozadénant

4-hydroxy-*N*-[4-méthoxy-7-(morpholin-4-yl)-1,3-benzothiazol-2-yl]-4-méthylpipéridine-1-carboxamide

tozadenant

4-hidroxi-*N*-[4-metoxi-7-(morfolin-4-il)-1,3-benzotiazol-2-il]-4-metilpiperidina-1-carboxamida $C_{19}H_{26}N_4O_4S$ **trebananibum #**

trebananib

immunoglobulin G1 Fc fragment fused with two synthetic polypeptides that bind the *Homo sapiens* ANGPT2 (angiotensin 2); methionyl (1) -gamma1 heavy chain fragment (2-228) [*Homo sapiens*IGHG1*01 hinge (EPKSC 1-5>del) (2-11), CH2 (12-121), CH3 (122-228)] fused, at the C-terminal end, with a synthetic polypeptide that comprises two 14-mer amino acid repeats that bind angiotensin 2 (229-287) [linker (229-235) -14-mer (236-249) -linker (250-271) -14-mer (272-285) -leucyl-glutamate]; (7-7':10-10')-bisdisulfide dimer

trébananib

immunoglobuline G1 fragment Fc fusionné à deux polypeptides synthétiques qui se lient à l'*Homo sapiens* ANGPT2 (angiotensine 2); méthionyl (1) -fragment de chaîne gamma1 (2-228) [*Homo sapiens*IGHG1*01 charnière (EPKSC 1-5>del) (2-11), CH2 (12-121), CH3 (122-228)] fusionné, à l'extrémité C-terminale, à un polypeptide synthétique qui comprend deux motifs répétés de 14 acides aminés qui se lient à l'angiotensine 2 (229-287) [linker (229-235) -14-mer (236-249) -linker (250-271) -14-mer (272-285) -leucyl-glutamate]; dimère (7-7':10-10')-bisdisulfure

trebananib

inmunoglobulina G1 fragmento Fc fusionado con dos polipéptidos sintéticos que se unen a la ANGPT2 (angiopoyetina 2) de *Homo sapiens*; metionil (1) -fragmento de cadena gamma1 (2-228) [*Homo sapiens*IGHG1*01 bisagra (EPKSC 1-5>del) (2-11), CH2 (12-121), CH3 (122-228)] fusionada con el extremo C-terminal de un polipéptido sintético que comprende dos secuencias repetidas de 14 aminoácidos que se unen a la angiopoyetina 2 (229-287) [conector (229-235) -14-mer (236-249) -conector (250-271) -14-mer (272-285) -leucil-glutamato]; dímero (7-7':10-10')-bisdisulfuro

```
MDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE 50
DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY 100
KCKVSNKALP APIEKTISKA KGQPREPQVY TLPFSRDEL TKNQVSLTCLV 150
KGFYPSDIAV EWESNGQPEN NYKTTTPFVLD SDGSFFLYSK LTVDKSRWQQ 200
GNVFSQCSVMH EALHNHYTQK SLSLSPGKGG GGGAQQEECE WDPWTCEHMG 250
SGSATGSGSGS TASSGSGSAT HQEECEWDPW TCEHMLE 287
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-chain 42'-102' 148'-206' 239'-246' 275'-282'

42'-102' 148'-206' 239'-246' 275'-282'

Inter-chains 7-7' 10-10'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

78, 78'

trelagliptinum

trelagliptin

2-({6-[(3*R*)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)methyl}-4-fluorobenzonitrile


trélagliptine

2-({6-[(3*R*)-3-aminopipéridin-1-yl]-3-méthyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)méthyl}-4-fluorobenzonitrile

trelagliptina

2-({6-[(3*R*)-3-aminopiperidin-1-il]-3-metil-2,4-dioxo-3,4-dihidropirimidin-1(2*H*)-il}metil)-4-fluorobenzonitrilo

C₁₈H₂₀FN₅O₂



umeclidinii bromidum

umeclidinium bromide


1-{2-[(benzyl)oxy]ethyl}-4-[hydroxydi(phenyl)methyl]-1-azabicyclo[2.2.2]octan-1-ium bromide

bromure d'uméclidinium

bromure de 1-{2-[(benzyl)oxy]éthyl}-4-[hydroxydi(phényl)méthyl]-1-azabicyclo[2.2.2]octanium

bromuro de umeclidinio

bromuro de 1-{2-[(bencil)oxi]etil}-4-[hidroxidi(fenil)metil]-1-azabíciclo[2.2.2]octan-1-io

$C_{29}H_{34}BrNO_2$ **vapedavirum**

vapedavir


3-ethoxy-6-{2-[1-(6-methylpyridazin-3-yl)piperidin-4-yl]ethoxy}-1,2-benzoxazole

vapedavir

3-éthoxy-6-{2-[1-(6-méthylpyridazin-3-yl)pipéridin-4-yl]éthoxy}-1,2-benzoxazole

vapedavir

3-etoxi-6-{2-[1-(6-metilpiridazin-3-il)piperidin-4-il]etoxi}-1,2-benzoxazol

 $C_{21}H_{26}N_4O_3$ **vonoprazanum**


vonoprazan

1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1*H*-pyrrol-3-yl]-*N*-methylmethanamine

vonoprazan

1-[5-(2-fluorophényl)-1-(pyridine-3-sulfonyl)-1*H*-pyrrol-3-yl]-*N*-méthylméthanamine

vonoprazán

1-[5-(2-fluorofenil)-1-(piridina-3-sulfonyl)-1*H*-pirrol-3-il]-*N*-metilmetanamina $C_{17}H_{16}FN_3O_2S$ **vortioxetinum**

vortioxetine


1-{2-[(2,4-dimethylphenyl)sulfonyl]phenyl}piperazine

vortioxétine

1-{2-[(2,4-diméthylphényl)sulfonyl]phényl}pipérazine

vortioxetina

1-{2-[(2,4-dimetilfenil)sulfanil]fenil}piperazina


$C_{18}H_{22}N_2S$ 

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Non Proprietary Names (Rec. INN): List 17
(*Chronicle of the WHO, 1977, Vol. 31, No. 10*)

p. 7 **oxitropii bromidum**
oxitropium bromide *replace the description and the structure by the following ones*


(1*R*,2*R*,4*S*,5*S*,7*s*,9*s*)-9-ethyl-7-[[*(2S)*-3-hydroxy-2-phenylpropanoyl]oxy]-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane bromide



Dénominations communes internationales recommandées (DCI Rec.): Liste 17
(*Chronique de l'OMS, Vol. 31, No. 10, 1977*)

p. 7 **oxitropii bromidum**
bromure d'oxitropium *remplacer la description et la structure par les suivantes*


bromure de (1*R*,2*R*,4*S*,5*S*,7*s*,9*s*)-9-éthyl-7-[[*(2S)*-3-hydroxy-2-phénylpropanoyl]oxy]-9-méthyl-3-oxa-9-azoniatricyclo[3.3.1.0^{2,4}]nonane



Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 17
(*Crónica de la OMS, Vol. 31, No. 10, 1977*)

p. 7 **oxitropii bromidum**
bromuro de oxitropio *sustitúyase la descripción y la estructura por las siguientes*

bromuro de (1*R*,2*R*,4*S*,5*S*,7*s*,9*s*)-9-etil-7-[[*(2S)*-2-fenil-3-hidroxipropanoil]oxi]-9-metil-3-oxa-9-azoniatriciclo[3.3.1.0^{2,4}]nonano



Recommended International Non Proprietary Names (Rec. INN): List 58
Dénominations communes internationales recommandées (DCI Rec.): Liste 58
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 58
(WHO Drug Information, Vol. 21, No. 3, 2007)


p. 260 **ulipristalum**

& 261 ulipristal

ulipristal

ulipristal

replace the structure by the following
remplacer la structure par la suivante
sustitúyase la estructura por la siguiente



Recommended International Non Proprietary Names (Rec. INN): List 60
Dénominations communes internationales recommandées (DCI Rec.): Liste 60
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 60
(WHO Drug Information, Vol. 22, No. 3, 2008)

p. 229 **conestatum alfa #**

conestat alfa

conestat alfa

conestat alfa

replace the structure by the following
remplacer la structure par la suivante
sustitúyase la estructura por la siguiente

```

NPNATSSSSQ DPESLQDRGE GKVATTVISK MLFVEPILEV SSLPTTNSTT 50
NSATKITANT TDEPTTQPTT EPTTQPTIQP TQPTTQLPTD SPTQPTTGSF 100
CPGPVTLCSL LESHSTEAVL GDALVDFSLK LYHAFSAMKK VETNMAFSPF 150
SIASLLTQVL LGAGENTKTN LESILSYPKD FTCVHQALKG FTTKGVTSVS 200
QIFHSPDLAI RDTFVNASRT LYSSSPRVLS NNSDANLELI NTWVAKNTNN 250
KISRLDLSLP SDTRLVLLNA IYLSAKWKT FDKKTRMEP FHFKNVSIKV 300
PMMNSKKYPV AHFIDQTLKA KVGQLQLSHN LSLVILVPQN LKRRLEDMEQ 350
ALSPSVFKAI MEKLEMSKFP PTLTLPLRIK VTTSQDMLSI MEKLEFFDFS 400
YDLNLCGLTE DPDLQVSAMQ HQTVLELTET GVEAAAAASAI SVARTLLVFE 450
VQQPFLEVLW DQGHKFFVFM GRVYDPRA 478

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 101-406 108-183

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
 Asn-3 Thr-26 Ser-42 Asn-47 Thr-49 Asn-59 Thr-61
 Thr-66 Thr-70 Thr-74 Asn-216 Asn-231 Asn-330

Recommended International Non Proprietary Names (Rec. INN): List 61
Dénominations communes internationales recommandées (DCI Rec.): Liste 61
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 61
(WHO Drug Information, Vol. 23, No. 1, 2009)

p. 67 **macitentanum**

macitentan

replace the chemical name by the following
N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}
pyrimidin-4-yl]-N-propylsulfuric diamide

Recommended International Non Proprietary Names (Rec. INN): List 62
Denominations communes internationales recommandées (DCI Rec.): Liste 62
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 62
(WHO Drug Information, Vol. 23, No. 3, 2009)

p. 263 & **solanezumabum #**
 264

solanezumab *replace the description and the structure by the following ones*
 solanezumab *remplacer la description et la structure par les suivantes*
 solanezumab *sustitúyase la descripción y la estructura por las siguientes*

immunoglobulin G1-kappa, anti-[*Homo sapiens* amyloid-beta (Abeta) peptide soluble monomer], humanized monoclonal antibody;
 gamma1 heavy chain [humanized VH (*Homo sapiens*IGHV3-23*04 (87.60%) - (IGHD)-IGHJ4*01) [8.8.5] (1-112) -*Homo sapiens*IGHG1*01 (113-442)], (215-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens*IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; (221-221'':224-224'')-bisdisulfide dimer

immunoglobuline G1-kappa, anti-[*Homo sapiens* amyloïde-bêta (Abeta) peptide monomère soluble], anticorps monoclonal humanisé;
 chaîne lourde gamma1 [VH humanisé (*Homo sapiens*IGHV3-23*04 (87.60%) - (IGHD)-IGHJ4*01) [8.8.5] (1-112) -*Homo sapiens*IGHG1*01 (113-442)], (215-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens*IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; dimère (221-221'':224-224'')-bisdisulfure

immunoglobulina G1-kappa, anti-[péptido amiloide-beta (Abeta) monomérico soluble de *Homo sapiens*], anticuerpo monoclonal humanizado;
 cadena pesada gamma1 [VH humanizado (*Homo sapiens*IGHV3-23*04 (87.60%) - (IGHD)-IGHJ4*01) [8.8.5] (1-112) -*Homo sapiens*IGHG1*01 (113-442)], (215-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens*IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; dímero (221-221'':224-224'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 EVQLVESGGG LVQPGGSLRL SCAASGFTFS RYSMSWVRQA PGKGLLEVAQ 50
 INSVGNTSTYY PDTVKGRTI SRDIAKNTLY LQMNSLRAED TAVYYCASGD 100
 YWGQGTLLTVT SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT 150
 VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTPSSSLGT QTYICNVNHK 200
 PSNTKVDKVK EPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR 250
 TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV 300
 LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR 350
 DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTP PVLDSGDSFF 400
 LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTKSLSLSP GK 442

Light chain / Chaîne légère / Cadena ligera
 DVVMTQSPLS LPVTLGQPAS ISCRSSQSLI YSDGNAYLHW FLQKPGQSPR 50
 LLIIYKVSNNR SGVPDRFSGS GSGTDFTLKI SRVEAEDGVV YYCSQSTHVP 100
 WTFGGQTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNFYYPREK 150
 VQWKVDNALQ SGNSQESVTE QDSKSTYSL SSTITLSKAD YEKHKVYACE 200
 VTHQGLSPV TKSFNREGC 219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H 22-96 139-195 256-316 362-420
 22"-96" 139"-195" 256"-316" 362"-420"
 Intra-L 23'-93' 139'-199'
 23'''-93''' 139'''-199'''
 Inter-H-L 215-219' 215"-219"
 Inter-H-H 221-221" 224-224"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H VH CDR2-IMGT N63:
 56, 56"
 H CH2 N84.4:
 292, 292"

Recommended International Non Proprietary Names (Rec. INN): List 64
Dénominations communes internationales recommandées (DCI Rec.): Liste 64
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 64
(WHO Drug Information, Vol. 23, No. 4, 2009)

p. 264 & **dalotuzumabum #**
 265

dalotuzumab
 dalotuzumab
 dalotuzumab

replace the description and the structure by the following ones
remplacer la description et la structure par les suivantes
sustitúyase la descripción y la estructura por las siguientes

immunoglobulin G1-kappa, anti-[*Homo sapiens* IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221), humanized monoclonal antibody; gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV4-61*08 (86.90%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -*Homo sapiens* IGHG1*03 (118-447)], (220-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-29*03 (84.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (226-226'':229-229'')-bisdisulfide dimer

immunoglobuline G1-kappa, anti-[*Homo sapiens* IGF1R (récepteur du facteur de croissance 1 analogue à l'insuline (IGF1-R, IGF-1R, CD221)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* IGHV4-61*08 (86.90%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -*Homo sapiens* IGHG1*03 (118-447)], (220-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-29*03 (84.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (226-226'':229-229'')-bisdisulfure

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IGF1R (receptor del factor de crecimiento similar a la insulina 1 (IGF1-R, IGF-1R, CD221)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* IGHV4-61*08 (86.90%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -*Homo sapiens* IGHG1*03 (118-447)], (220-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-29*03 (84.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (226-226'':229-229'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLQESGPG LVKPSSETLSL TCTVSGYSIT GGYLWNWIRQ PPGKLEWIG 50
 YISYDGTNNY KPSLKDRTVI SRDTSKNQFS LKLSSTVTAAD TAVVYCARYG 100
 RVFFDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPSSSLGTQTYIC 200
 NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
 LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK FEEQYNSTY 300
 RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
 LPFSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTPPPVLD 400
 DGSFFLYSKL TVDKSRWQQG NVFSCSVME ALHNHYTQKS LSLSPGK 447

Light chain / Chaîne légère / Cadena ligera
 DIVMTQSPLS LPVTPEEPAS ISCRSSQSIIV HSNNTYQLQW YLQKPGQSPQ 50
 LLIIYKVSRL YGVDPDRFSGS GSGTDFTLKI SRVEAEDGVV YYCFQGSHPV 100
 WFTGQGTQVE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNFYPREAK 150
 VQWKVDNALQ SGNSQESVTE QDSKSTYSLS SFTLTLTKAD YEKHKVYACE 200
 VTHQGLSPV TKSFNREGC 219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 144-200 261-321 367-425
 22"-96" 144"-200" 261"-321" 367"-425"

Intra-L 23'-93' 139'-199'
 23'''-93''' 139'''-199'''

Inter-H-L 220-219' 220'-219'
 Inter-H-H 226-226'' 229-229''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4
 297, 297''

Recommended International Non Proprietary Names (Rec. INN): List 67
 Dénominations communes internationales recommandées (DCI Rec.): Liste 67
 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67
 (WHO Drug Information, Vol. 26, No. 1, 2012)

p. 70 lipegfilgrastimum #

lipegfilgrastim

replace the description and the structure by the following ones

lipegfilgrastim

remplacer la description et la structure par les suivantes

lipegfilgrastim

sustitúyase la descripción y la estructura por las siguientes

pegylated granulocyte colony stimulating factor (human short isoform);
 $O^{3,137}$ -[3,5-dideoxy-5-[(N-[ω-methoxypoly(oxyethylene)]carbonyl)glycyl]amino]-
D-glycero-α-D-galacto-non-2-ulopyranosylonic acid)-(2→6)-2-(acetyl-amino)-2-deoxy-
α-D-galactopyranosyl]-des-(37-39)-[1-methionine]human granulocyte
colony-stimulating factor (G-CSF, pluripoietin)


facteur de stimulation de colonie de granulocytes (isoforme court humain) pégylé;
 $O^{3,137}$ -{[acide 3,5-didéoxy-5-[(N-[[w-méthoxypoly(oxyéthylène)]carbonyl)glycyl]amino]-
D-glycéro- α -D-galacto-non-2-ulopyranosylonique]-(2 \rightarrow 6)-2-(acétylamino)-2-déoxy-
 α -D-galactopyranosyl]-dès-(37-39)-[1-méthionine]}facteur humain de stimulation de
colonie de granulocytes (G-CSF, pluripolitéine)

factor de estimulación de colonias de granulocitos (isoformo corto humano) pegilado; $O^{3,137}$ -{ácido 3,5-didesoxi-5-[(N-{[ω-metoxipoli(oxietileno)]carbonil}glicil)amino]-D-glicero-α-D-galacto-non-2-ulopiranosilónico}-(2→6)-2-(acetilamino)-2-desoxi-α-D-galactopiranosil]-dés-(37-39)-[1-metionina]factor humano de estimulación de colonias de granulocitos (G-CSF, pluripoyetina)

MTPLGPASSL	PQSFLCLKLE	QVRKIQGDGA	ALQEKL---C	ATYKLCHPPEE	50
LVVLGHSLGI	PWAPLSSCCP	QALQLAGCLS	QLHSGFLFYQ	GLLQALEGIS	100
FLGPTLVDTI	QLDVAADFAT	IWQQMEELAQ	APALQPTQGA	MPAFASAFQR	150
PAGGLVVASH	LQSFVFSYR	VLRLHLQPM			178

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
40-46 68-78

Modified residues / Résidu modifié / Residuo modificado



- # Electronic structure available on Mednet: <http://mednet.who.int/>
- # Structure électronique disponible sur Mednet: <http://mednet.who.int/>
- # Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.